OBJECTIVE: To compare reticulocyte responses of once-per-week erythropoietin (EPO) dosing with 3-times-a-week dosing in preterm infants. STUDY DESIGN:Infants weighing ≤ 1500 g and ≥ 7 days of age were randomized to once-per-week EPO, 1200 U/kg/dose, or 3-times-a-week EPO, 400 U/kg/dose, subcutaneously for 4 weeks, along with iron and vitamin supplementation. Complete blood counts, absolute reticulocyte counts (ARCs), transfusions, phlebotomy losses, and adverse events were recorded. RESULTS:Twenty preterm infants (962 ± 55 g, 27.9 ± 0.4 weeks, 17 ± 3 days of age) were enrolled. Groups were similar at baseline. Infants in both groups had increased ARCs, which were similar between treatment groups at the start and end of 4 weeks. Hematocrit remained stable, and similar numbers of transfusions were administered. No adverse effects of either dosing schedule were noted. CONCLUSIONS:Preterm infants respond to weekly EPO by increasing ARCs and maintaining hematocrit. We speculate that once-per-week EPO dosing might be beneficial to preterm infants requiring increased erythropoiesis.
RCT Entities:
OBJECTIVE: To compare reticulocyte responses of once-per-week erythropoietin (EPO) dosing with 3-times-a-week dosing in preterm infants. STUDY DESIGN:Infants weighing ≤ 1500 g and ≥ 7 days of age were randomized to once-per-week EPO, 1200 U/kg/dose, or 3-times-a-week EPO, 400 U/kg/dose, subcutaneously for 4 weeks, along with iron and vitamin supplementation. Complete blood counts, absolute reticulocyte counts (ARCs), transfusions, phlebotomy losses, and adverse events were recorded. RESULTS: Twenty preterm infants (962 ± 55 g, 27.9 ± 0.4 weeks, 17 ± 3 days of age) were enrolled. Groups were similar at baseline. Infants in both groups had increased ARCs, which were similar between treatment groups at the start and end of 4 weeks. Hematocrit remained stable, and similar numbers of transfusions were administered. No adverse effects of either dosing schedule were noted. CONCLUSIONS: Preterm infants respond to weekly EPO by increasing ARCs and maintaining hematocrit. We speculate that once-per-week EPO dosing might be beneficial to preterm infants requiring increased erythropoiesis.
Authors: G Calapai; M C Marciano; F Corica; A Allegra; A Parisi; N Frisina; A P Caputi; M Buemi Journal: Eur J Pharmacol Date: 2000-08-11 Impact factor: 4.432
Authors: L G Weiss; N Clyne; J Divino Fihlho; C Frisenette-Fich; J Kurkus; B Svensson Journal: Nephrol Dial Transplant Date: 2000-12 Impact factor: 5.992
Authors: A L Sirén; M Fratelli; M Brines; C Goemans; S Casagrande; P Lewczuk; S Keenan; C Gleiter; C Pasquali; A Capobianco; T Mennini; R Heumann; A Cerami; H Ehrenreich; P Ghezzi Journal: Proc Natl Acad Sci U S A Date: 2001-03-20 Impact factor: 11.205
Authors: R K Ohls; R A Ehrenkranz; L L Wright; J A Lemons; S B Korones; B J Stoll; A R Stark; S Shankaran; E F Donovan; N C Close; A Das Journal: Pediatrics Date: 2001-10 Impact factor: 7.124
Authors: Xiaobing Yu; John J Shacka; Jeffrey B Eells; Carlos Suarez-Quian; Ronald M Przygodzki; Bojana Beleslin-Cokic; Chyuan-Sheng Lin; Vera M Nikodem; Barbara Hempstead; Kathleen C Flanders; Frank Costantini; Constance Tom Noguchi Journal: Development Date: 2002-01 Impact factor: 6.868
Authors: Robin K Ohls; Beena D Kamath-Rayne; Robert D Christensen; Susan E Wiedmeier; Adam Rosenberg; Janell Fuller; Conra Backstrom Lacy; Mahshid Roohi; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Hannah Peceny; Daniel C Cannon; Jean R Lowe Journal: Pediatrics Date: 2014-05-12 Impact factor: 7.124
Authors: Robin K Ohls; Robert D Christensen; Beena D Kamath-Rayne; Adam Rosenberg; Susan E Wiedmeier; Mahshid Roohi; Conra Backstrom Lacy; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Ron Schrader; Jean R Lowe Journal: Pediatrics Date: 2013-06-17 Impact factor: 7.124
Authors: Leeann R Pavlek; Brian K Rivera; Charles V Smith; Joanie Randle; Cory Hanlon; Kristi Small; Edward F Bell; Matthew A Rysavy; Sara Conroy; Carl H Backes Journal: J Pediatr Date: 2021-04-21 Impact factor: 6.314